Published July 20, 2021 | Version v1
Journal article Open

Advanced mesoporous silica nanocarriers in cancer theranostics and gene editing applications

  • 1. BioSense Institute, University of Novi Sad, Dr Zorana Djindjica 1, 21000 Novi Sad, Serbia
  • 2. School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland

Description

Targeted nanomaterials for cancer theranostics have been the subject of an expanding volume of research studies in recent years. Mesoporous silica nanoparticles (MSNs) are particularly attractive for such applications due to possibilities to synthesize nanoparticles (NPs) of different morphologies, pore diameters and pore arrangements, large surface areas and various options for surface functionalization. Functionalization of MSNs with different organic and inorganic molecules, polymers, surface-attachment of other NPs, loading and entrapping cargo molecules with on-desire release capabilities, lead to seemingly endless prospects for designing advanced nanoconstructs exerting multiple functions, such as simultaneous cancer-targeting, imaging and therapy. Describing composition and multifunctional capabilities of these advanced nanoassemblies for targeted therapy (passive, ligand-functionalized MSNs, stimuli-responsive therapy), including one or more modalities for imaging of tumors, is the subject of this review article, along with an overview of developments within a novel and attractive research trend, comprising the use of MSNs for CRISPR/Cas9 systems delivery and gene editing in cancer. Such advanced nanconstructs exhibit high potential for applications in image-guided therapies and the development of personalized cancer treatment.

Notes

The authors would like to thank the Ministry of Education, Science and Technological Development of the Republic of Serbia (Grant No: 451-03-9/2021-14/200358), the Science Fund of the Republic of Serbia, PROMIS (PRECAST Grant No: 6060755) and European Union's Horizon 2020 research and innovation programme under grant agreement No. 952259 (NANOFACTS) and grant agreement No. 758887 (REACT) for financial support.

Files

1-s2.0-S0168365921003722-main.pdf

Files (6.7 MB)

Name Size Download all
md5:6a8668253e2163f73fe806a81a9654e5
6.7 MB Preview Download

Additional details

Funding

REACT – REsponsive theranostic nanosystems for Advanced Cancer Treatment 758887
European Commission
NANOFACTS – Networking Activities for Nanotechnology-Facilitated Cancer Theranostics 952259
European Commission